Senior Editor, Diagnostic Imaging
The MRI-based Early Recurrence Individualized Score (MERIS) demonstrated an 18 percent higher C-index than the Barcelona Clinic Liver Cancer (BCLC) staging system for predicting early recurrence of hepatocellular carcinoma (HCC) for patients who had resection of solitary HCC tumors.
Iodine density measurements with photon-counting detector CT offered higher than 93 percent sensitivity and 95 percent specificity for differentiating between bland and neoplastic portal vein thrombosis in newly published research.
Reportedly providing automation of 14 standard and advanced cardiac MRI views in less than 30 seconds, the SmartHeart also facilitates a 75 percent reduction in breath holds for basic MRI views.
Initial breast cancer risk scoring with adjunctive AI assessment of screening mammograms increased by approximately 80 percent in a subsequent screening round for women with breast cancer, according to research findings presented at the European Congress of Radiology.
Utilized within the cloud-native Genesis Radiology Workspace, the newly FDA-cleared View reportedly facilitates anytime, anywhere efficiency with seamless access to enhanced visualization and AI-powered tools.
Catch up on the top radiology content of the past week.
Designed to enhance product stability at higher radioactive concentrations, the PSMA PET imaging agent Pylarify TruVu (piflufolastat F 18) may facilitate enhanced supply flexibility and access for men with suspected recurrence or metastasis of prostate cancer.
While large language models (LLMs) may offer the promise of workflow efficiencies and streamlined documentation in radiology, LLMs may also increase exposure to cybersecurity risks, according to a presentation at the European Congress of Radiology (ECR).
The Harrison.ai software is reportedly the first AI software to gain clearance for acute infarct triage on non-contrast CT scans.
Emerging research reveals higher attrition rates among cardiothoracic radiologists, breast radiologists and nuclear medicine physicians in comparison to other subspecialties in radiology.
The MEDRAD MRXperion MR Injection System is cleared for use with low-field and high-field MRI platforms, including 7T MRI.
Reportedly the first generative AI model in radiology to receive the FDA breakthrough device designation, Cognita Chest X-Ray (CXR) facilitated an 18 percent improvement in CXR interpretation efficiency based on preliminary data.
In addition to significantly reduced interpretation time, researchers found that adjunctive AI with ultrasound resulted in accuracy improvements of greater than 7 percent for nodule echogenicity and 16 percent for nodule margin assessments.
Combining an 85 cm bore, high resolution and accelerated image reconstruction, the Rembra CT platform can reportedly handle up to 270 CT exams a day.
In comparison to LI-RADS version 2018 for MRI assessment, the use of perfluorobutane-enhanced ultrasound incorporating Kupffer-phase findings yielded comparable sensitivity and specificity for detecting hepatocellular carcinoma (HCC) nodules < 20 mm in high-risk patients, according to new research.
Offering reportedly seamless integration into workflows for prenatal evaluations and real-time decision-making, the cloud-based Delivery Date AI software was trained on millions of ultrasound images from diverse pregnancies.
In a recent interview, Ashesh Jani, M.D., discussed pertinent findings in two post-hoc studies from the SPOTLIGHT trial that examined the efficacy of 18F-flotufolastat PET/CT for detecting biochemical recurrence and bone metastases in patients with prostate cancer.
Full approval of PNT2003, a radioequivalent of Lutathera (lutetium Lu 177 dotatate), is subject to a 30-month stay — triggered by a Hatch-Waxman patent litigation — that is reportedly set to expire in June 2026.
Catch up on the top radiology content of the past week.
In a recent interview, Brian Helfand, M.D., Ph.D., discussed key findings from a multicenter prospective trial, presented at the ASCO-GU symposium, that compared the PET radiotracers 18F-flotufolastat and 18F piflufolastat for urinary radioactivity and detection of PCa recurrence.
Radiologist turnover continues to be a significant challenge with higher turnover rates among women, metropolitan radiologists and those in non-academic settings, according to newly published research.
In a recent interview from the ASCO-GU conference. Daniel George, M.D., discussed new study findings with 177Lu-PSMA-617 for the treatment of older taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) and potential implications for future research.
The FDA clearance for the AI-enabled chest X-ray software qXR-Detect reportedly includes detection of findings in the lung, pleura, hila and heart, bone and mediastinum.
Offering AI-powered automation features and advanced imaging capabilities, the new LOGIQ E10 series, the LOGIC Fortis™ and the LOGIQ Totus™ ultrasound platforms will be introduced at the European Congress of Radiology in March.
In a recent interview, Nina Kottler, M.D., discussed the agility of agentic AI to achieve system-level goals in radiology, the need for transparency and how agentic AI may affect the future of radiology.
The AKY-1189 agent was designed for targeting of positive Nectin-4 expressing tumors that reportedly occur in 80 to 90 percent of patients with urothelial cancer.
The use of adjunctive AI led to higher detection of breast cancer in women with dense breasts as well as increased detection of invasive cancer and lobular cancer, according to new research involving over 100,000 screening DBT exams.
In a recent interview, Jeremy Heit, M.D., Ph.D., discussed key neuroimaging takeaways from changes to the updated guideline from the American Heart Association and the American Stroke Association for early evaluation and management of patients with acute ischemic stroke.
Catch up on the top radiology content of the past week.
Previously approved by the FDA in 2022, the macrocyclic gadolinium-based MRI contrast agent gadopiclenol can now be utilized to detect lesions with abnormal vascularity in the central nervous system and other parts of the body for children under the age of two.
